Mononucleotide mutation in-situ imaging method based on allosteric HDA and CRISPR / Cas12b

Through the combination of allosteric HDA and CRISPR/Cas12b systems, high specificity and sensitivity detection of BRAF V600E mutations in thyroid cancer is achieved, solving the problems of misdiagnosis and over-medical problems in the prior art, and supporting the formulation of individualized medical plans.

CN118995930APending Publication Date: 2024-11-22CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411254176.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art has low sensitivity and specificity in the detection of BRAF V600E mutations of thyroid cancer, and requires the extraction of nucleic acids, resulting in misdiagnosis and over-medical problems, making it difficult to make rapid and economical diagnosis in primary hospitals.

Method used

Using single nucleotide mutation in situ imaging method based on allosteric HDA and CRISPR/Cas12b, the specific amplification and recognition of the BRAF V600E mutant gene is achieved through thermodynamic changes and artificial mismatch insertion, and rapid use of signal reporting probes Test.

Benefits of technology

High specificity and sensitivity detection of BRAF V600E mutations has been achieved, which reduces the rate of misdiagnosis and missed diagnosis, improves diagnostic accuracy, and supports the formulation of individualized medical plans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995930A_ABST
    Figure CN118995930A_ABST
Patent Text Reader

Abstract

The invention discloses a mononucleotide mutation in-situ imaging method based on allosteric HDA and CRISPR / Cas12b, and belongs to the technical field of mononucleotide mutation in-situ imagines.The mononucleotide mutation in-situ imaging method comprises the steps that firstly, a BRAF V600E mutant gene serves as a detection target to synthesize nucleic acid, and the nucleic acid is dissolved in a buffer solution for use; c basic group mismatch is introduced into the No.3 site of the end 3 of the HAD primer to obtain an allosteric primer, and specific amplification of the BRAF V600E mutant gene is realized by means of thermodynamic change; then sgRNA of the CRISPR / Cas12b system is modified, and the artificial mismatch insertion position of the sgRNA is as follows: a single base is mutated on the No.18 site; then, a modified CRISPR / Cas12b system is used for carrying out specific recognition on mutant genes of an amplification product, the trans-shear activity of the amplification product is activated, and a signal report probe is rapidly sheared. Through the mode, the high-specificity and high-sensitivity detection of the BRAF V600E mutant gene is realized by virtue of an allosteric HDA and CRISPR / Cas12b system subjected to manual insertion and mismatch transformation, and the problems of TC misdiagnosis and missed diagnosis and excessive medical treatment are solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of in situ imaging of single nucleotide mutations, and in particular to an in situ imaging method of single nucleotide mutations based on allosteric HDA and CRISPR / Cas12b. Background Art

[0002] Thyroid cancer (TC) is a malignant tumor originating from the thyroid follicular epithelium or parafollicular epithelial cells and is the most common malignant tumor in the head and neck. Patients with thyroid cancer can benefit from thyroidectomy and have a good prognosis. However, in recent years, many countries have reported problems of overdiagnosis and intervention of the thyroid gland to varying degrees, which has increased the health and economic burden on patients. Therefore, the accurate diagnosis of thyroid cancer remains a clinical problem that needs to be solved urgently.

[0003] At present, thyroid fine needle aspiration biopsy (FNA) is the main method for evaluating the malignancy of thyroid nodules. However, due to the lack of typical cytological specificity of some pathological types of thyroid nodules, 10%-35% of thyroid puncture samples cannot be clearly diagnosed. Moreover, cytological examination is easily affected by factors such as specimen preparation and staining, and depends on the experience accumulation and diagnostic level of different pathologists. Molecular diagnosis can assist in the differentiation of benign and malignant tumors, thyroid cancer risk stratification, and prognosis assessment, which is convenient for the formulation of individualized diagnosis and treatment plans. Among them, BRAF V600E mutation is a commonly used biomarker for thyroid cancer. Among them, in the most common TC-papillary thyroid carcinoma (PTC, accounting for 80%-90%), the incidence of BRAF V600E mutation is about 40%-70%. In addition, TC with BRAF V600E mutation shows clinical characteristics such as high invasiveness, easy lymph node metastasis, and easy recurrence. It is insensitive to radioactive iodine treatment, but sensitive to targeted drugs such as multikinase inhibitor sorafenib.

[0004] In summary, the sensitive and specific detection of BRAF V600E in FNA has important medical significance in the diagnosis, prognosis evaluation and treatment guidance of TC.

[0005] Sanger sequencing is the "gold standard" for gene mutation detection. It can detect known mutation sites, and the results are accurate and reliable. However, the sensitivity and specificity are relatively low, and the analysis time is long. Amplification Refractory Mutation System PCR (ARMS-PCR) has improved detection sensitivity and specificity, but it is still unable to detect low-abundance mutations and requires a specific experimental environment and precise temperature control equipment. In addition, all of the above methods require the extraction of nucleic acids, which results in the loss of in situ mutation information; they require dedicated sites and additional samples, making them difficult to carry out in primary hospitals.

[0006] Therefore, molecular diagnosis of BRAF V600E in thyroid cancer FNA urgently requires the development of a new simple and rapid in situ detection technology that is economical, has low sample requirements, and is specific and sensitive.

[0007] Based on this, the present invention designs an in situ imaging method of single nucleotide mutations based on allosteric HDA and CRISPR / Cas12b to solve the above problems. Summary of the invention

[0008] In view of the above-mentioned shortcomings of the prior art, the present invention provides an in situ imaging method for single nucleotide mutations based on allosteric HDA and CRISPR / Cas12b.

[0009] To achieve the above objectives, the present invention is implemented through the following technical solutions:

[0010] The in situ imaging method of single nucleotide mutation based on allosteric HDA and CRISPR / Cas12b, first, the nucleic acid is synthesized with the BRAFV600E mutant gene as the detection target and dissolved in buffer for later use; a C base mismatch is introduced at position 3 of the 3' end of the HAD primer to obtain an allosteric primer, and with the help of thermodynamic changes, the specific amplification of the BRAF V600E mutant gene is achieved; then the sgRNA of the CRISPR / Cas12b system is modified, and the position of the artificial mismatch insertion is: a single base mutation at position 18; then the modified CRISPR / Cas12b system is used to specifically identify the mutant gene of the amplified product, activate its trans-cleavage activity, and quickly cleave the signal reporter probe.

[0011] Furthermore, the signal reporter probe is FAM-TTATT-BHQ1.

[0012] Furthermore, the amplification conditions are: magnesium ion concentration is 4 mM, sodium ion concentration is 2 mM, and dATP concentration is 0.75 mM.

[0013] Furthermore, the sequence of the allosteric primer AS-RP-3C is:

[0014] GTAAAAATAGGTGATTTTGGTCTAGCTACCGA.

[0015] Furthermore, the sequence of sgRNA-a18 obtained by sgRNA modification is:

[0016] GUCUAGAGGACAGAAUUUUUCACGGGGUGUGCCAAUGGCCACUUUCCAGGU GGCAAAGCCCGUUGAGCUUCUCAAAUCUGAGAACUGGCACGACUAGCUACAGAGA AAUCU.

[0017] In order to better achieve the purpose of the present invention, the present invention also provides an allosteric primer AS-RP-3C for use in the single nucleotide mutation in situ imaging method based on allosteric HDA and CRISPR / Cas12b, and the sequence of the allosteric primer AS-RP-3C is: GTAAAAATAGGTGATTTTGGTCTAGCTACCGA.

[0018] In order to better achieve the purpose of the present invention, the present invention also provides a sgRNA-a18 for use in the single nucleotide mutation in situ imaging method based on allosteric HDA and CRISPR / Cas12b, and the sequence of sgRNA-a18 is:

[0019] GUCUAGAGGACAGAAUUUUUCACGGGGUGUGCCAAUGGCCACUUUCCAGGU GGCAAAGCCCGUUGAGCUUCUCAAAUCUGAGAACUGGCACGACUAGCUACAGAGA AAUCU.

[0020] Compared with the prior art, the present invention has the following beneficial effects: the present invention uses the artificially inserted mismatched modified allosteric HDA and CRISPR / Cas12b system to achieve high specificity and sensitivity detection of the BRAF V600E mutant gene, solving the problems of TC misdiagnosis, missed diagnosis and over-medicalization. The present invention integrates the patient's clinical information and traditional pathological test results to customize individualized medical plans and maximize the benefits to patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention, and for ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0022] Figure 1 This is the detection result of allosteric HAD;

[0023] Figure 2 Optimize the results for amplification experimental conditions;

[0024] Figure 3 Energy prediction results of sgRNA binding to the target based on the location and number of artificial mismatch insertions;

[0025] Figure 4 The effect of introducing mismatches into sgRNA on detection efficiency;

[0026] Figure 5 Verification of in situ imaging capabilities at the cellular level. DETAILED DESCRIPTION

[0027] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0028] To achieve rapid, specific, sensitive and in situ detection of the BRAF V600E mutant gene, two key issues need to be addressed: low abundance detection and specific identification.

[0029] On the one hand, the clustered regularly interspaced short palindromic repeats and associated proteins (CRISPR / Cas) system is used to achieve specific recognition of mutant genes. The CRISPR / Cas system is an acquired immune system that prokaryotes rely on to resist the invasion of foreign genes from bacteriophages or plasmids. In view of the flexible targeting ability of the CRISPR / Cas12 system, and its characteristics of rapidity, accuracy, sensitivity, and economy, the detection method based on it is recognized as an ideal next-generation rapid and sensitive nucleic acid on-site detection technology. Cas12b (also known as C2c1) is a type of nuclease mediated by crRNA and tracrRNA (or fused sgRNA alone). It is more heat-resistant than Cas12a and shows a low tolerance for single-base mutations (SNVs). It is of great application value in the field of mutant gene identification. In addition, the high-conversion trans-scission activity of the Cas12 family can achieve signal amplification and increase the sensitivity of the detection strategy.

[0030] On the other hand, helicase dependent amplification (HDA) is used to achieve specific amplification of SNVs and achieve SNV enrichment in disguise. HDA is an in vitro efficient constant temperature gene amplification technology that simulates the DNA replication mechanism in animals. It mainly consists of three parts: helicase, single strand binding protein (SSB) and DNA polymerase. Using the above elements, the HDA reaction is amplified through a three-step cycle of template separation, primer hybridization and primer extension, similar to PCR. The difference is that the unwinding of dsDNA is assisted by DNA helicase, rather than the thermal cycling step used in PCR. Through synchronous chain reactions at a constant temperature, HDA can achieve more than one million times the amplification of the target sequence. At present, HDA has been applied to the detection of long nucleic acid target substances. At the same time, with the discovery of heat-resistant helicases, the specificity and sensitivity of HAD for pathogen and SNV detection have been improved.

[0031] In view of this, the present invention constructs a BRAF V600E mutant gene detection strategy based on the CRISPR / Cas12b system, and combines the HDA isothermal amplification technology to establish a new method for rapid in situ detection of thyroid FNA with high specificity and sensitivity. Combined with clinical HE staining and immunohistochemical staining technology, accurate diagnosis of thyroid cancer is achieved, the diagnostic accuracy of thyroid cancer is improved, and precision medicine is promoted. Specifically, the BRAF V600E mutant gene is first used as the detection target, and the specific HDA amplification of the mutant gene is achieved with the help of thermodynamically modified primers, and then the modified CRISPR / Cas12b system is used to further specifically identify the mutant gene, activate its efficient trans-splicing activity, and quickly cut the signal reporter probes marked with fluorescent probes and quenching probes at both ends, so that the quenched fluorescence is restored, and the target gene is rapidly and sensitively detected; after optimizing the experimental conditions, the method of the present invention is applied to the in situ imaging of the BRAF V600E mutant gene in FNA cell smears, eliminating the misdiagnosis caused by false positives and false negatives caused by nucleic acid extraction, and improving the detection accuracy. Subsequently, the method of the present invention is integrated with HE staining and immunohistochemical staining techniques to realize information integration of samples, further improving the accuracy of diagnosis. The implementation of the present invention will establish a new method for rapid, sensitive, specific, and in situ identification of BRAF V600E genotypes, providing a more efficient testing method for accurate diagnosis and individualized treatment of clinical thyroid cancer.

[0032] Embodiment 1

[0033] In some embodiments, a method for in situ imaging of single nucleotide mutations based on allosteric HDA and CRISPR / Cas12b comprises the following steps:

[0034] 1. Establishment of a new method for single-base mutation detection based on allosteric HDA and CRISPR / Cas12b

[0035] 1.1. First, synthesize nucleic acid using BRAF V600E mutation gene as detection target and dissolve it in TE buffer for later use;

[0036] 1.2. Specific HDA amplification of mutant genes was achieved with the help of thermodynamically modified primers (FP and AS-PR-origin);

[0037] Specifically, different base types (A\T\C\G), number (1\2\3) and position (1\2\3 at the end) of mismatches were introduced at the 3 ends of the HDA primer, and the specific amplification of the BRAF V600E mutant gene was achieved by thermodynamic change (changing the bases (position and type) of AS-PR-origin to AS-RP-3G, AS-RP-3T, AS-RP-3C, AS-RP-2C, AS-RP-2T, AS-RP-GT, AS-RP-TT, AS-RP-CT in Table 1);

[0038] Preferably, Figure 1 The results showed that the introduction of a C base mismatch at position 3 of the 3 end of the HAD primer had the highest discrimination factor (DF), which could achieve the greatest degree of discrimination between the wild type and the mutant type. This allosteric primer was used for subsequent experiments.

[0039] Next, important experimental parameters in amplification were optimized, specifically, the concentrations of sodium ions, magnesium ions, and dATP were optimized to achieve efficient amplification of mutant targets.

[0040] like Figure 2 As shown, when the magnesium ion concentration is 4 mM, the sodium ion concentration is 2 mM, and the dATP concentration is 0.75 mM, the detection system has the highest DF, so these three experimental conditions are used for subsequent experiments.

[0041] 1.3. Then, the modified CRISPR / Cas12b system was used to specifically identify the mutant gene of the amplified product and activate its efficient trans-cleavage activity, and quickly cleave the signal reporter probe (FAM-TTATT-BHQ1) labeled with a fluorescent probe and a quenching probe at both ends, so that the quenched fluorescence was restored, and the target gene was detected quickly and sensitively;

[0042] Specifically, the sgRNA of the CRISPR / Cas12b system was modified to optimize the location and number of artificial mismatch insertions to further increase detection specificity and sensitivity.

[0043] like Figure 3 and Figure 4As shown in B, the software was used to obtain the binding energy of the target and sgRNA at different positions and numbers of mismatches, and the binding energy difference between the wild type and the mutant was further calculated. The results showed that the energy difference between the wild type and the mutant was the largest when single base mutations occurred at 15, 16, 17, 18, 19 and when there was no mutation insertion. Therefore, mutant nucleic acids were synthesized according to these sets of experimental conditions for experimental verification.

[0044] like Figure 4 As shown in Figure C, when a single mutation occurs at position 18, it has the highest DF and can sensitively distinguish between wild type and mutant type. Therefore, this experimental condition was used for subsequent experiments.

[0045] 2. Establishment of a new strategy for in situ imaging of BRAF V600E mutation in thyroid FNA smears

[0046] Using BRAF V600E homozygous mutant cell lines and homozygous wild-type cell lines as cell models (for example, melanoma cell lines (A375) and colorectal cancer cell lines (HCT116) as cell models), the in situ imaging capability of this strategy at the cellular level and the lower limit of mutation abundance detection were explored.

[0047] First, Sanger sequencing was used to verify the mutation of the cell line. Then, in situ imaging experiments were performed on the slides of the two cell models. The results showed that only the positive cell lines showed obvious green fluorescence, indicating that this scheme can image single base mutations in situ. Figure 5 As shown, A375 is a BRAF V600E homozygous mutant cell line, and HCT116 is a homozygous wild-type cell line.

[0048] 3. Clinical Application

[0049] 60 pathological specimens diagnosed with thyroid cancer were collected and subjected to in situ imaging, HE staining and immunohistochemical staining according to the method of the present invention. The test results and clinical case information were integrated, combined with treatment guidelines and medication guidelines to achieve customized individualized medical plans for patients.

[0050] The nucleic acid sequences used in the present invention are shown in Table 1. Sequence numbers 1-10 are primers for HAD amplification. Sequence numbers 11-14 are targets synthesized in liquid phase for verifying detection feasibility and performance optimization. Sequence numbers 15-21 are sgRNA and reporter probes used in the Cas12b system.

[0051] Table 1 Nucleotide sequences

[0052]

[0053]

[0054] 1. The present invention uses the artificially inserted mismatch-modified allosteric HDA and CRISPR / Cas12b system to achieve high-specificity and sensitive detection of the BRAFV600E mutant gene, solving the problems of misdiagnosis, missed diagnosis and over-medicalization of TC.

[0055] 2. The present invention integrates the patient's clinical information and traditional pathological test results to customize individualized medical plans and maximize the benefits to patients.

[0056] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. Such modifications or replacements will not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. In situ imaging of single nucleotide mutations based on allosteric HDA and CRISPR / Cas12b, It is characterized in that First, nucleic acid was synthesized with BRAF V600E mutant gene as the detection target and dissolved in buffer for later use; a C base mismatch was introduced at position 3 of the 3' end of the HAD primer to obtain an allosteric primer, and with the help of thermodynamic changes, specific amplification of the BRAF V600E mutant gene was achieved; then the sgRNA of the CRISPR / Cas12b system was modified, and the position of the artificial mismatch insertion was: a single base mutation at position 18; then the modified CRISPR / Cas12b system was used to specifically identify the mutant gene of the amplified product, activate its trans-cleavage activity, and quickly cleave the signal reporter probe.

2. The method for in situ imaging of single nucleotide mutations based on allosteric HDA and CRISPR / Cas12b according to claim 1, It is characterized in that The signal reporter probe is FAM-TTATT-BHQ1.

3. The method for in situ imaging of single nucleotide mutations based on allosteric HDA and CRISPR / Cas12b according to claim 2, It is characterized in that The amplification conditions are as follows: magnesium ion concentration is 4 mM, sodium ion concentration is 2 mM, and dATP concentration is 0.75 mM.

4. The method for in situ imaging of single nucleotide mutations based on allosteric HDA and CRISPR / Cas12b according to claim 3, It is characterized in that The sequence of the allosteric primer AS-RP-3C is: GTAAAAATAGGTGATTTTGGTCTAGCTACCGA.

5. The method for in situ imaging of single nucleotide mutations based on allosteric HDA and CRISPR / Cas12b according to claim 4, It is characterized in that The sequence of sgRNA-a18 obtained by sgRNA modification is: GUCUAGAGGACAGAAUUUUUCACGGGGUGUGCCAAUGGCCACUUUCCAGGU GGCAAAGCCCGUUGAGCUUCUCAAAUCUGAGAACUGGCACGACUAGCUACAGAGA AAUCU.

6. An allosteric primer AS-RP-3C for use in the single nucleotide mutation in situ imaging method based on allosteric HDA and CRISPR / Cas12b according to claim 1, It is characterized in that The sequence of the allosteric primer AS-RP-3C is: GTAAAAATAGGTGATTTTGGTCTAGCTACCGA.

7. An sgRNA-a18 for use in the single nucleotide mutation in situ imaging method based on allosteric HDA and CRISPR / Cas12b according to claim 1, It is characterized in that The sequence of sgRNA-a18 is: GUCUAGAGGACAGAAUUUUUUUACACGGGUGUGCCAAUGGCCACUUUCCAGGU GGCAAAGCCCGUUGAGCUUCUCAAAUCUGAGAACUGGCACGACUAGCUACAGGA AAUCU.